Novartis Settles Lawsuit with Henrietta Lacks’ Estate Over HeLa Cell Line

The estate of Henrietta Lacks has reached a settlement with pharmaceutical giant Novartis, resolving a lawsuit alleging the company unjustly profited from the use of her cells – known as the HeLa cell line – without her knowledge or consent. The agreement, finalized this month in federal court in Maryland, brings an finish to one facet of the Lacks family’s ongoing legal efforts to address the commercialization of cells taken from Lacks during cancer treatment in 1951. While the specific terms of the settlement remain confidential, it marks the second such agreement reached by the estate with a biomedical company in recent years.

Henrietta Lacks, a Black woman and mother of five, underwent treatment for cervical cancer at Johns Hopkins Hospital. During her treatment, cells were taken from her tumor without her awareness. These cells proved to have an extraordinary ability to reproduce indefinitely in laboratory settings, becoming the first “immortalized” human cell line. The HeLa cell line has since been instrumental in countless medical breakthroughs, including the development of the polio vaccine, genetic mapping, and, more recently, research related to COVID-19 vaccines. However, for decades, the Lacks family received no compensation for the use of these cells, despite their profound impact on science, and medicine.

A History of Exploitation and the Pursuit of Justice

The lawsuit against Novartis, filed in 2024, sought “the full amount of its net profits obtained by commercializing the HeLa cell line,” arguing that the cells were “stolen” and that Novartis had unjustly benefited from their use. This case follows a similar settlement reached in 2023 with Thermo Fisher Scientific Inc., where the Lacks estate argued the company continued to profit from the cells even after the origins and ethical concerns surrounding their acquisition became widely known. As reported by the Associated Press, the family’s legal team has indicated they may pursue further claims against other companies.

The core of the Lacks family’s argument centers on the ethical implications of taking human biological material without informed consent, particularly within a historical context of systemic racism and exploitation in the medical system. The HeLa cell line’s story has become a prominent example of bioethical concerns, raising questions about patient rights, intellectual property, and the equitable distribution of benefits derived from medical research. The family’s legal battles aim to address these historical injustices and establish a precedent for protecting the rights of individuals whose biological materials contribute to scientific advancement.

The Unique Properties of HeLa Cells and Their Impact

What made HeLa cells so remarkable – and so valuable to researchers – was their ability to divide and reproduce indefinitely in a laboratory setting. Most human cells have a limited lifespan, but HeLa cells bypassed this limitation, providing a continuous source of identical cells for experimentation. Stat News details five key ways Henrietta Lacks changed medical science, highlighting the cell line’s role in everything from cancer research to understanding the effects of radiation and toxins. This immortality allowed for standardized testing and reproducible results, accelerating the pace of scientific discovery.

The widespread use of HeLa cells also led to the development of new technologies and techniques in cell culture and genetic research. They were crucial in mapping the human genome and continue to be used in studies exploring a wide range of diseases. However, this widespread use also occurred without the Lacks family’s knowledge or consent, and without any financial benefit accruing to them.

Ongoing Litigation and the Broader Implications

While the settlements with Novartis and Thermo Fisher Scientific represent significant steps forward, the Lacks family’s legal pursuit is not yet complete. Lawsuits against Ultragenyx Pharmaceutical and Viatris remain active, indicating a continued determination to hold companies accountable for the commercialization of HeLa cells. The family’s attorneys have also suggested the possibility of filing additional complaints, signaling a broader strategy to address the historical and ongoing exploitation of Henrietta Lacks’ cells.

The legal battles surrounding HeLa cells have sparked a wider conversation about the ethical responsibilities of researchers and companies when utilizing human biological materials. It has prompted discussions about informed consent, benefit-sharing, and the need for greater transparency in the commercialization of biological resources. The case also underscores the importance of addressing historical injustices and ensuring that the contributions of individuals like Henrietta Lacks are recognized and respected.

Johns Hopkins’ Role and the Question of Profit

Johns Hopkins Hospital, where the cells were originally taken, has stated that it never sold or profited from the HeLa cell line itself. However, many companies have patented methods and technologies that utilize the cells, generating substantial revenue. This distinction highlights the complex legal and ethical landscape surrounding the commercialization of biological materials. The Lacks family’s lawsuits focus on the companies that have directly profited from the use of the cells, rather than Johns Hopkins, which initially obtained them.

The story of Henrietta Lacks and the HeLa cell line gained wider public attention with the publication of Rebecca Skloot’s bestselling book, “The Immortal Life of Henrietta Lacks,” and the subsequent HBO film adaptation. These works brought the family’s story to a broader audience, raising awareness of the ethical issues involved and fueling the push for justice.

What Comes Next: Evolving Standards for Biological Material Use

The settlements reached by the Lacks estate are likely to have a ripple effect on the field of biomedical research. They may encourage companies to proactively address the ethical implications of using human biological materials and to consider benefit-sharing arrangements with individuals and communities whose contributions are essential to scientific progress. Further legal challenges and evolving regulatory frameworks could also play a role in shaping future standards for the use of human biological resources. The ongoing litigation serves as a reminder of the need for ongoing vigilance and a commitment to ethical principles in all aspects of medical research and innovation.